Tinengotinib

The 'Intrahepatic Cholangiocarcinoma (ICC)- Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of ICC treatments, detailing the pipeline landscape, emerging drugs, and key players. Notable drugs include Tinengotinib (TransThera Biosciences), Nanvuranlat (J-Pharma Co., Ltd.), and NXP 800 (Nuvectis Pharma, Inc.), all in various stages of development. The report also highlights therapeutic assessments, pipeline development activities, and key collaborations.